Octreotide 200 micrograms/ml solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

octreotide 200 micrograms/ml solution for injection

pfizer healthcare ireland - octreotide acetate - solution for injection - 200 microgram(s)/millilitre - somatostatin and analogues; octreotide

Octreotide 50 micrograms/1 ml solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

octreotide 50 micrograms/1 ml solution for injection

pfizer healthcare ireland - octreotide acetate - solution for injection - 50 microgram(s)/millilitre - somatostatin and analogues; octreotide

Octreotide 500 micrograms/1 ml solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

octreotide 500 micrograms/1 ml solution for injection

pfizer healthcare ireland - octreotide acetate - solution for injection - 500 microgram(s)/millilitre - somatostatin and analogues; octreotide

OCTREOTIDE LAR SANDOZ octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite pac Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide lar sandoz octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite pac

novartis pharmaceuticals australia pty ltd - octreotide -

OCTREOTIDE LAR SANDOZ octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite pac Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide lar sandoz octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite pac

novartis pharmaceuticals australia pty ltd - octreotide -

OCTREOTIDE LAR SANDOZ octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite pac Australia - English - Department of Health (Therapeutic Goods Administration)

octreotide lar sandoz octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite pac

novartis pharmaceuticals australia pty ltd - octreotide -

OCTREOTIDE ACETATE- octreotide acetate injection, solution United States - English - NLM (National Library of Medicine)

octreotide acetate- octreotide acetate injection, solution

heritage pharmaceuticals inc. - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration). in patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown i

SANDOSTATIN LAR 30 MG Israel - English - Ministry of Health

sandostatin lar 30 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

SANDOSTATIN LAR 20 MG Israel - English - Ministry of Health

sandostatin lar 20 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

SANDOSTATIN LAR 10 MG Israel - English - Ministry of Health

sandostatin lar 10 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.